Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up

Paediatric Drugs

Volumn 2, Issue 1, 2000, Pages 1-9

  Guilleminault, Christian ^a   Pelayo, Rafael ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; LEUKOCYTE ANTIGEN; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; OXYBATE SODIUM; PEMOLINE; PROTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; VILOXAZINE;

ANTIGEN DETECTION; BEHAVIOR THERAPY; CATAPLEXY; DISEASE TRANSMISSION; DRUG INDUCED DISEASE; FOLLOW UP; HALLUCINATION; HUMAN; NARCOLEPSY; PARALYSIS; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SLEEP;

EID: 0033979673     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200002010-00001     Document Type: Review

References (61)

1. 1. Aldrich MS, Narcolepsy, Neurology 1992; 42 (7 Suppl. 6): 34-43
2. 2. Guilleminault C, Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998; 43 (1): 135-42
3. 3. Passouant P. Doctor Gelineau (1828-1906): narcolepsy centennial. Sleep 1981; 4 (3): 241-6
4. 4. Daniels L. Narcolepsy. Medicine 1934; 13: 1-122
5. 5. Yoss RE, Daly DD. On the treatment of narcolepsy. Med Clin North Am 1968; 52 (4): 781-7
6. 6. Rechtschaffen A, Dement W. Studies on the relation of narcolepsy, cataplexy, and sleep with low voltage random EEG activity.Res Publ Assoc Res Nerv Ment Dis 1967; 45: 488-505
7. 7. Hishikawa Y. Neurophysiological characteristics of nercoleptic symptoms [in French]. Rev Neurol Paris 1967; 116 (6): 675-6
8. 8. Hublin C, Partinen M, Kaprio J, et al. Epidemiology of narcolepsy.Sleep 1994; 17 Suppl. 8: S7-12
9. 9. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43 (1): 88-97
10. 10. Guilleminault C, Heinzer R, Mignot E, et al.Investigations into the neurologic basis of narcolepsy. Neurology 1998; 50 (2 Suppl. 1): S8-15
11. 11. Hishikawa Y, Shimizu T. Physiology of REM sleep, cataplexy, and sleep paralysis. Adv Neurol 1995; 67: 245-71
12. 12. Guilleminault C, Stoohs R, Clerk A, et al. A cause of excessive daytime sleepiness: the upper airway resistance syndrome [see comments]. Chest 1993; 104 (3): 781-7
13. 13. Carskadon MA, Dement WC, Mitler MM, et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9 (4); 519-24
14. 14. Honda Y, Juji T, Matsuki K, et al. HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Sleep 1986; 9 (1); 133-42
15. 15. Mignot E, Hayduk R, Black J, et al. HLA DQB1 *0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20 (11): 1012-20
16. 16. Juji T, Satake M, Honda Y, et al. HLA antigens in Japanese patients with narcolepsy: all the patients were DR2 positive. Tissue Antigens 1984; 24 (5): 316-9
17. 17. Guilleminault C, Grumet C. HLA-DR2 and narcolepsy: not all narcoleptic-cataplectic patients are DR2 [letter], Hum Immunol 1986; 17 (1): 1-2
18. 18. Kramer RE, Dinner DS, Braun WE, et al. HLA-DR2 and narcolepsy.Arch Neurol 1987; 44 (8): 853-5
19. 19. Roth B, Nevsimalova S, Sonka K, et al.A study of the occurrence of HLA DR2 in 124 narcoleptics: clinical aspects, Schweiz Arch Neurol Psychiatr 1988; 139 (4): 41-51
20. 20. Billiard M, Seignalet J, Besset A, et al.HLA-DR2 and narcolepsy.Sleep 1986; 9 (1): 149-52
21. 21. Guilleminault C, Mignot E, Grumet FC. Familial patterns of narcolepsy [see comments]. Lancet 1989; II (8676): 1376-9
22. 22. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50 (2 Suppl. 1): S16-22
23. 23. Billiard M. Narcolepsy. Clinical features and aetiology. Ann Clin Res 1985; 17 (5): 220-6
24. 24. Mitler MM, Boysen BG, Campbell L, et al.Narcolepsy-cataplexy in a female dog.Exp Neurol 1974; 45 (2): 332-40
25. 25. Mignot E, Guilleminault C, Bowersox S, et al.Role of central alpha-1 adrenoceptors in canine narcolepsy.J Clin Invest 1988; 82 (3); 885-94
26. 26. Mignot E, Wang C, Rattazzi C, et al.Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment.Proc Natl Acad Sci USA 1991; 88 (8): 3475-8
27. 27. Mignot E, Tafti M, Dement WC, et al.Narcolepsy and immunity.Adv Neuroimmunol 1995; 5 (1); 23-37
28. 28. Kanbayashi T, Nishino S, Tafti M, et al.Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy.Neuroreport 1996; 7 (12): 1881-6
29. 29. Kanbayashi T, Nishino S, Tafti M, et al.Thalidomide, immune modulation and narcolepsy [letter].Sleep 1996; 19 (2): 116
30. 30. Hayduk R, Flodman P, Spence MA, et al.HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy.Sleep 1997; 20 (10): 850-7
31. 31. Kaprio J, Hublin C, Partinen M, et al.Narcolepsy-like symptoms among adult twins.J Sleep Res 1996; 5 (1): 55-60
32. 32. Lankford DA, Wellman JJ, O'Hara C. Posttraumatic narcolepsy in mild to moderate closed head injury, Sleep 1994; 17 (8 Suppl.): S25-8
33. 33. Bassetti C, Aldrich MS. Idiopathic hypersomnia: a series of 42 patients. Brain 1997; 120 Pt 8: 1423-35
34. 34. Billiard M, Merle C, Carlander B, et al.Idiopathic hypersomnia.Psychiatry Clin Neurosci 1998; 52 (2): 125-9
35. 35. Fry JM. Treatment modalities for narcolepsy. Neurology 1998; 50 (2 Suppl. 1): S43-8
36. 36. Dahl RE, Holttum J, Trubnick L. A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 1994; 33 (6): 834-41
37. 37. Mitler MM. Evaluation of treatment with stimulants in narcolepsy. Sleep 1994; 17 (8 Suppl.): S103-6
38. 38. Mitler MM, Shafor R, Hajdukovich R, et al.Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline,Sleep 1986; 9 (1): 260-4
39. 39. Iijima S, Sugita Y, Teshima Y, et al.Therapeutic effects of mazindol on narcolepsy.Sleep 1986; 9 (1): 265-8
40. 40. Lyons TJ, French J. Modafinil: the unique properties of a new stimulant. Aviat Space Environ Med 1991; 62 (5): 432-5
41. 41. Engber TM, Koury EJ, Dennis SA, et al.Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil.Neurosci Lett 1998; 241 (2-3): 95-8
42. 42. Ferraro L, Antonelli T, O'Connor WT, et al.Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers.Biol Psychiatry 1997; 42 (12): 1181-3
43. 43. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997; 283 (2): 757-69
44. 44. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12 (5): 695-700
45. 45. Billiard M, Besset A, Montplaisir J, et al.Modafinil: a double-blind multicentric study.Sleep 1994; 17 (8 Suppl.): S107-12
46. 46. Besset A, Chetrit M, Carlander B, et al.Use of modafinil in the treatment of narcolepsy: a long term follow-up study.Neurophysiol Clin 1996; 26 (1): 60-6
47. 47. Broughton RJ, Fleming JA, George CF, et al.Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy.Neurology 1997; 49 (2): 444-51
48. 48. Wong YN, King SP, Laughton WB, et al.Single-dose pharmacokinetics of modafinil and methylphenidate given alone or in combination in healthy male volunteers.J Clin Pharmacol 1998; 38 (3): 276-82
49. 49. Simon P, Hemet C, Ramassamy C, et al.Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995; 5 (4): 509-14
50. 50. Mignot E, Nishino S, Guilleminault C, et al.Modafinil binds to the dopamine uptake carrier site with low affinity.Sleep 1994; 17 (5): 436-7
51. 51. Ferraro L, Antonelli T, O'Connor WT, et al.The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998; 253 (2): 135-8
52. 52. Engber TM, Dennis SA, Jones BE, et al.Brain regional sub-strates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine.Neuroscience 1998; 87 (4): 905-11
53. 53. Scharf MB, Lai AA, Branigan B, et al.Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients.Sleep 1998; 21 (5): 507-14
54. 54. Galloway GP, Frederick SL, Staggers Jr FE, et al.Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence [see comments].Addiction 1997; 92 (1): 89-96
55. 55. Lammers GJ, Arends J, Declerck AC, et al.Gammahydroxy-butyrate and narcolepsy: a double-blind placebo-controlled study.Sleep 1993; 16 (3): 216-20
56. 56. Bedard MA, Montplaisir J, Godbout R, et al.Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989; 12 (1): 29-36
57. 57. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate, Can J Neurol Sci 1979; 6 (1): 1-6
58. 58. Scrima L, Hartman PG, Johnson Jr FH, et al.The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study.Sleep 1990; 13 (6): 479-90
59. 59. Mignot E, Renaud A, Nishino S, et al.Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology 1993; 113 (1): 76-82
60. 60. Nishino S, Arrigoni J, Shelton J, et al.Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds.Sleep 1993; 16 (8): 706-12
61. 61. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy: a pilot study, Neurology 1994; 44 (4): 707-9